Jasper Therapeutics Statistics
Total Valuation
JSPR has a market cap or net worth of $19.01 million. The enterprise value is -$8.30 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JSPR has 28.00 million shares outstanding. The number of shares has increased by 31.43% in one year.
| Current Share Class | 28.00M |
| Shares Outstanding | 28.00M |
| Shares Change (YoY) | +31.43% |
| Shares Change (QoQ) | +72.30% |
| Owned by Insiders (%) | 1.19% |
| Owned by Institutions (%) | 53.23% |
| Float | 21.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.62 |
| P/TBV Ratio | 4.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.30.
| Current Ratio | 2.62 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -230.31% and return on invested capital (ROIC) is -148.07%.
| Return on Equity (ROE) | -230.31% |
| Return on Assets (ROA) | -88.16% |
| Return on Invested Capital (ROIC) | -148.07% |
| Return on Capital Employed (ROCE) | -361.32% |
| Weighted Average Cost of Capital (WACC) | 20.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.81M |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.96% in the last 52 weeks. The beta is 3.20, so JSPR's price volatility has been higher than the market average.
| Beta (5Y) | 3.20 |
| 52-Week Price Change | -82.96% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 2.24 |
| Relative Strength Index (RSI) | 16.15 |
| Average Volume (20 Days) | 454,043 |
Short Selling Information
The latest short interest is 3.12 million, so 11.14% of the outstanding shares have been sold short.
| Short Interest | 3.12M |
| Short Previous Month | 3.34M |
| Short % of Shares Out | 11.14% |
| Short % of Float | 14.26% |
| Short Ratio (days to cover) | 8.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.58M |
| Pretax Income | -75.80M |
| Net Income | -75.80M |
| EBITDA | -80.53M |
| EBIT | -81.58M |
| Earnings Per Share (EPS) | -$3.95 |
Full Income StatementBalance Sheet
The company has $28.69 million in cash and $1.24 million in debt, with a net cash position of $27.46 million or $0.98 per share.
| Cash & Cash Equivalents | 28.69M |
| Total Debt | 1.24M |
| Net Cash | 27.46M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 4.15M |
| Book Value Per Share | 0.15 |
| Working Capital | 21.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.16 million and capital expenditures -$7,000, giving a free cash flow of -$77.17 million.
| Operating Cash Flow | -77.16M |
| Capital Expenditures | -7,000 |
| Depreciation & Amortization | 1.06M |
| Net Borrowing | n/a |
| Free Cash Flow | -77.17M |
| FCF Per Share | -$2.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JSPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.42% |
| Shareholder Yield | -31.42% |
| Earnings Yield | -395.66% |
| FCF Yield | -402.79% |
Analyst Forecast
The average price target for JSPR is $15.50, which is 2,182.27% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.50 |
| Price Target Difference | 2,182.27% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -25.66% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 4, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 4, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |
